IPSEN IN BRIEF 2023

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.

OUR STRATEGY AND INVESTMENT CASE

FOCUS. TOGETHER. FOR PATIENT & SOCIETY.

1. MAXIMIZE OUR BRANDS
2. STRENGTHEN PIPELINE
3. DRIVE EFFICIENCIES
4. FOCUS ON CULTURE

ENTIRE FOCUS ON SPECIALTY CARE (ONCOLOGY, RARE DISEASE AND NEUROSCIENCE)
Opportunities for further growth across the three therapy areas

GLOBAL FOOTPRINT
A well-balanced & expanded presence around the world

EXPANDING PIPELINE
A good mix of new molecules and lifecycle management

EXTERNAL-INNOVATION STRATEGY
Fueling the expansion of the pipeline across the therapy areas

STRONG BALANCE SHEET & CASH GENERATION
Free cash flow >€800m in 2022

IPSEN KEY FIGURES

€3.0bn TOTAL SALES (2022)
5,400 COLLEAGUES
100+ COUNTRIES WHERE IPSEN MEDICINES ARE MARKETED

The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs:

Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
**SALES BY THERAPEUTIC AREA AND MEDICINE IN €M (GROWTH AT CONSTANT EXCHANGE RATES)**

- **Oncology**
  - Somatuline: 1,218 (+5.6%)
  - Decapeptyl: 530 (+12.4%)
  - Cabometyx: 449 (+23.9%)
  - Onivyde: 162 (+14.1%)
  - Other Oncology: 8 (-12.3%)

- **Rare Disease**
  - Rare Disease: 41 (-18.3%)

- **Neuroscience**
  - Dysport: 594 (+29.4%)
  - Other Neuroscience: 11 (+51.2%)

**TOTAL SPECIALTY CARE SALES IN €M**

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>2,381</td>
</tr>
<tr>
<td>2021</td>
<td>2,643</td>
</tr>
<tr>
<td>2022</td>
<td>3,025</td>
</tr>
</tbody>
</table>

**A STRONG PLATFORM FOR SUSTAINABLE GROWTH**

- **External innovation**
- **Growth platforms**

**GEOGRAPHIC BREAKDOWN**

- **North America**: 34%
- **Europe**: 41%
- **Rest of World**: 25%

**THE CORE PILLARS OF GENERATION IPSEN**

**ENVIRONMENT**

- **Emissions**: GHG emission-reduction trajectory: officially certified by the Science Based Targets initiative²
- **Renewables**: 90% renewable electricity for all global operations
- **Fleet**: Launched Fleet for Future programs

**PATIENTS**

- **Access**: Partnership with Access Accelerated: continued to support communities that lack sufficient access to healthcare
- **Ukraine**: €1.5m donation to the Red Cross and Tulipe, plus medicine donations

**PEOPLE**

- **Diversity**: Women: 48% of the Global Leadership Team
- **Employer of choice**: In 23 countries
- **Community**: 44% of colleagues participated in Ipsen’s Community Day

**GOVERNANCE**

- **Certification**: ISO 37001 certification for anti-corruption management systems
- **Compliance**: Continued rigorous compliance with highest ethics and compliance standards

---

²A collaboration between the CDP, the United Nations Global Compact, the World Resources Institute and the World Wide Fund for Nature. GHG: greenhouse gas.